Search

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Meetings Sponsor Program

The European Hematology Association (EHA) is a membership organization serving clinicians and researchers with an active interest in hematology in Europe and beyond. We bring together relevant stakeholders to promote excellence in patient care through education, research, and advocacy.

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more

Infections in Hematology

The SWG on Infection in Hematology was founded in 2017 and follows four main goals:

Develop and share clinically useful tools: Many hematologists create checklists and pathways for quick and easy reference.

Read more